What are HIV protease inhibitor combination drugs?

HIV protease inhibitor combination drugs are pharmacologic agents that share a common mechanism (typically targeting HIV protease). 1 are currently marketed, with 3 more in clinical development.

What are the marketed HIV protease inhibitor combination drugs?

Marketed HIV protease inhibitor combination drugs include Lopinavir/r plus saquinavir.

HIV protease inhibitor combination

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 3 in Phase 3

This page covers all HIV protease inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HIV protease.

Targets

HIV protease

Marketed (1)

Lopinavir/r plus saquinavir · The HIV Netherlands Australia Thailand Research Collaboration · Infectious Disease / Virology
This combination of two protease inhibitors blocks HIV protease to prevent viral replication, with ritonavir boosting lopinavir levels.

Phase 3 pipeline (3)

Lopinavir/ritonavir (drug) · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · Infectious Disease
Lopinavir/ritonavir is a combination protease inhibitor that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.
LPV/RTV · ViiV Healthcare · Infectious Disease
LPV/RTV is a combination of two protease inhibitors that block HIV protease, preventing the maturation of HIV virions and reducing viral replication.
Kaletra Tablets · Ottawa Hospital Research Institute · Infectious Disease / Virology
Kaletra is a combination of lopinavir and ritonavir that inhibits HIV protease to prevent viral replication.

Patent intelligence

hiv protease inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates